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Analysis of a Successful Immune Response
against Hepatitis C Virus
and allow it to escape host immune responses (Kumar
et al., 1994; Weiner et al., 1995). Although responses
that terminate viremia have eluded detailed analysis,
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Amy J. Weiner,² David Y. Chien,²
Michael Houghton,² Peter Parham,* studies of CD41Th1-cell proliferation have suggested
that early multispecific responses favor resolution (Mis-and Christopher M. Walker²§
*Department of Structural Biology sale et al., 1996), with specificity against nonstructural
protein 3 (NS3) playing a role (Diepolder et al., 1995).Department of Microbiology and Immunology
Sherman Fairchild Building On the other hand, although antibodies appear to select
for HCV variants (Kumar et al., 1994), evidence that anti-Stanford University School of Medicine
Stanford, California 94305-5400 bodies resolve infection remains elusive. For example,
a recent report of successful antibody responses during²Chiron Corporation
4650 Horton Street early infection described similar responses in a substan-
tial proportion of patients who failed to clear virus (Koba-Emeryville, California 94608
yashi et al., 1997).
Because acute hepatitis C has been difficult to study,
most investigation has focused on chronically infectedSummary
individuals, both in humans, the natural host, and chim-
panzees, the only other species known to support viralTo investigate the type of immunity responsible for
resolution of hepatitis C virus (HCV) infection, we mon- replication (Koziel et al., 1992; Cerny et al., 1995a; Ko-
walski et al., 1996; Rehermann et al., 1996). Studies withitored antibody and intrahepatic cytotoxic T lympho-
cyte (CTL) responses during acute (,20 weeks) infec- the genotype 1 strain, HCV-1, indicate that the common
chimpanzee, Pan troglodytes, provides a faithful modeltion in chimpanzees. Two animals who terminated
infection made strong CTL but poor antibody re- of human hepatitis C (Walker, 1997), with most animals
developing chronic infection that can even result in he-sponses. In both resolvers, CTL targeted at least six
viral regions. In contrast, animals developing chronic patocellular cancer (Muchmore et al., 1988). Sharing of
orthologous immune-response genes between chim-hepatitis generated weaker acute CTL responses. Ex-
tensive analysis of the fine specificity of the CTL in one panzees and humans augments the fidelity of this model
(Lawlor et al., 1990; Bontrop et al., 1995; Watkins, 1995;resolver revealed nine peptide epitopes and restric-
tion by all six MHC class I allotypes. Every specificity Cooper et al., 1998). Therefore, chimpanzees are being
used in HCV vaccine development, despite considerableshown during acute hepatitis persisted in normal liver
tissue more than 1 yr after resolution. These results cost.
The study reported here took advantage of an ongoingsuggest that CD81CTL are better correlated with pro-
tection against HCV infection than antibodies. vaccine development effort that was aimed at stimulat-
ing humoral immunity in chimpanzees using recombi-
nant HCV envelope glycoproteins (Houghton et al., 1991,
Introduction 1996; Choo et al., 1994). This provided us with oppor-
tunity to simultaneously study HCV-specific CTL re-
Hepatitis C virus (HCV) is a major cause of chronic liver sponses throughout the course of infection in some
disease, cirrhosis, and hepatocellular cancer worldwide animals. Because most fail to resolve, and bulk CTL
(Alter, 1996). Only a minority of people (,30%) resolve responses wane or at least fluctuate following resolu-
acute hepatitis, with most (z3.5 million in the USA alone) tion, initial experiments were conducted in chronically
developing life-long infection. Vaccine development is infected animals (e.g., see Kowalski et al., 1996). In the
therefore essential but has been slowed by poor under- course of that work (and see Missale et al., 1996; Reher-
standing of the type of immunity that naturally termi- mann et al., 1996; Nelson et al., 1997), there were hints
nates HCV infection. Principal factors hampering prog- that the onset of cell-mediated immunity might effect
ress are the low rate of spontaneous resolution (Sharara at least transient control of virus. Importantly, these early
et al., 1996), which is rarely observed contemporane- studies allowed us to develop methods for characteriza-
ously, and methods for the thorough analysis of suc- tion of intrahepatic CTL epitopes in chimpanzees to-
cessful responses in protected individuals. gether with their (Patr) MHC class I restriction elements
Most people infected with HCV fail to resolve despite (Cooper et al., 1996; Kowalski et al., 1996). In the current
generating virus-specific antibody and T cell responses. study, we therefore set out to prospectively examine
At least part of the explanation for HCV's evasiveness antibody and intrahepatic CTL responses in a group of
probably lies in the mutability of its RNA genome, six HCV-inoculated chimpanzees.
causing it to exist as a mixture of related sequences
(ªquasispeciesº) that evolve under immune selection Results
³ To whom correspondence should be addressed (e-mail: scooper@ Analysis of Anti-HCV Responses in Six
cmgm.stanford.edu).
Chimpanzees during Acute Hepatitis§ Present address: Department of Pediatrics, College of Medicine
The levels of HCV RNA (using RT-PCR [Weiner et al.,and Public Health, The Ohio State University, Children's Hospital
W503, Columbus, Ohio 43205. 1995]) and liver transaminases were determined in pre-
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Figure 2. HCV Antibody Responses
Circulating HCV antibodies were measured
using multiantigen ELISA (Kuo et al., 1989;
Chien et al., 1992) in each study animal at
indicated timepoints. Symbols depicting re-
spective HCV antibody specificities are dia-
mond, CORE; square, E1/E2; triangle, E2;
multiplication sign, NS3; star, NS4; and circle,
NS5. Antibody titres are depicted on the y
axes and sampled timepoints on the abscis-
sae. Envelope antibodies present in Hulk at
the time of HCV inoculation reflects prechal-
lenge vaccination with recombinant E1/E2
antigens.
and postinoculation sera, and HCV-specific CTL and using a sensitive RT-PCR assay, and hepatic transami-
nases remained within the normal range. In addition,antibody responses were examined at the same time-
points. Antibody responses were evaluated using a sen- liver histology has shown no evidence of an inflamma-
tory infiltrate or ultrastructural abnormality (data notsitive multiantigen ELISA (Chien et al., 1992; Chien,
1993). CTL responses were assessed using liver-derived shown).
Whereas the resolvers quickly generated a broad CTLbulk CD81 T cells assayed against a panel of autologous
target cells infected with recombinant vaccinia viruses response, the four animals that developed chronic infec-
tion either failed to generate detectable CTL (Briggsie) or(rVV) expressing different regions of the HCV polyprotein
(Figure 1). Except for Hulk, who had been vaccinated developed an early response that was directed against
relatively fewer viral proteins (Figure 1). In this spectrumwith envelope glycoproteins, none of the animals pos-
sessed HCV antibodies prechallenge (Figure 2). Simi- of CTL response, CherylB displayed an intermediate
level of response but failed to terminate infection. Theselarly, none of the chimpanzees displayed HCV-specific
CTL responses before viral inoculation (data not shown). data suggest that unless a certain threshold of CTL
response is achieved during acute hepatitis, infectionFour individuals became persistently infected with
HCV, while two, Todd and LouLou, resolved infection is likely to persist. Note, in contrast, that when the num-
ber of CTL specificities are compared beyond about 16within 11 and 8 weeks, respectively (Figure 1). Termina-
tion of infection in Todd and LouLou correlated precisely weeks no difference between responses in resolvers
and nonresolvers is apparent.with the onset of an intrahepatic CTL response directed
against multiple HCV proteins. No cytotoxic responses In contrast to their CTL responses, neither Todd nor
LouLou made a strong antibody response. Todd devel-were observed against targets infected with wild-type
VV (data not shown) or against uninfected targets. At oped very low titre antibodies against envelope (E) and
a nonstructural (NS3) antigen, and LouLou exhibited athe peak of the responses, 11 weeks post challenge in
Todd and 5 weeks post challenge in LouLou, CTL were transient and barely detectable response against NS5.
Briggsie and CherylB gradually developed antibodiesshown to target five regions of the HCV polyprotein. Both
individuals were followed for z18 months and remained to nonstructural antigens but became persistently in-
fected. Similarly, Hulk, who possessed vaccine-induceddisease free by conventional clinical criteria: HCV RNA
has been repeatedly undetectable in peripheral blood envelope antibodies at the time of HCV inoculation, also
Figure 1. Comparison between CTL Responses in Six Chimpanzees Inoculated with HCV
Intrahepatic CD81 cells expanded from liver biopsies taken pre- and, at the indicated timepoints, post inoculation were tested for capacity
to lyse autologous BLCL targets. For Todd, LouLou, CherylB, and Hulk, some later timepoints (.16 weeks) are also shown. BLCL were either
unmanipulated (NoVV) or infected with recombinant vaccinia viruses (rVV) expressing different HCV proteins, as indicated in the lower panel.
This schematic also shows the relative orientation of the structural (core [C], envelope 1 [E1], envelope 2 [E2]), and nonstructural (NS) proteins
of the HCV-1 polyprotein (Choo et al., 1991). P7 is a putative 62 residue protein of unknown function. Each CTL assay was performed for 4
hr in duplicate wells at 3 effector:target (E:T) ratios. Amounts of percent specific lysis (PSL) are shown, with significant values depicted within
boxes; significance was interpreted when PSL $32 corresponding control values at $2 E:T ratios if $20% specific lysis was observed at the
maximum E:T ratio. PSL values ,1% have been rounded off to ª1.º Coincident with each liver biopsy, serum was assayed for HCV RNA and
for alanine aminotransferase (ALT) levels. The results of semiquantitative RT-PCR assays for HCV RNA are indicated on an ascending scale
of 11→41. A dash indicates that viral RNA was not detected. Elevated levels of ALT, indicating hepatitis, are indicated with an asterisk. Note
that hepatitis does not correlate consistently with CTL activity (e.g., Briggsie) or viremia (Winny).
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Figure 3. Initial Characterization of Five HCV-
Specific CD81CTL Lines Expanded from a
Liver Biopsy Obtained from Todd 11 Weeks
after HCV Challenge
The nomenclature for each CTL line is indi-
cated. HCV specificity was established using
the recombinant vaccinia viruses (rVV) de-
picted in Figure 1. The rVV expressing HCV
antigens for each CTL line are also shown,
together with the results of cytotoxicity as-
says demonstrating the chimpanzee MHC
(Patr) class I restriction of respective CTL
lines. Each of Todd's six class I alleles were
expressed in the class I±deficient B cell line
721.221, forming a target panel. Autologous
BLCL, expressing all six class I allotypes and
ªwild-typeº 721.221 were also included as
positive and negative controls, respectively.
Target cells were infected with antigen-con-
taining rVV and incubated at 378C for 3 hr with relevant CTL lines at 3 E:T ratios. Significant levels of percent specific lysis (PSL) are indicated
in bold type within boxes; significance was interpreted when PSL $32 corresponding control values at $ 2 E:T ratios if $20% specific lysis
was observed at the maximum E:T ratio.
developed nonstructural antibodies but progressed to Thus, the breadth of Todd's acute-phase CTL response
reflected utilization of at least four class I allotypes.chronic infection (Figure 2).
Thus, in comparison with the four individuals devel- To map the viral epitopes bound by each class I allo-
type, we used synthetic HCV peptides spanning eachoping chronic infection, a consistent difference between
early CTL responses was observed in both resolvers, recombinant protein and identified those that sensitized
the transfectant targets for lysis by the respective CTLwhereas no distinguishing pattern of antibody response
was demonstrated. Taken together, these data sug- lines. The HCV epitopes determined by these assays
are summarized in Table 1. During the course of thisgested that CTL, not antibodies, mediated protection in
both individuals. Because Todd was the first study ani- investigation, CTL line 1F lost viability, precluding deter-
mination of its epitope. Initial data suggested, however,mal to terminate viremia, he was selected for most de-
tailed investigation. that it shared identical specificity with line 6C. Charac-
terization of these CTL not only emphasized the breadth
of the antiviral response but also provided a reference
CTL Present during HCV Resolution Display against which the existence of HCV-specific CD81T cell
Multiple MHC Class I Restriction memory could be subsequently tested.
To dissect the MHC class I±mediated response coinci-
dent with disappearance of HCV, lines of virus-specific Persistence of HCV-Specific CD81CTL
CTL were established from a portion of Todd's eleventh Following Acute Hepatitis C
week liver biopsy (see Figure 1) and their specificities Seventy-six weeks after Todd terminated HCV infection,
determined. In standard cytotoxicity assays, these non- fresh PBMC were restimulated with the epitopic pep-
antigenically expanded CTL lines were tested against tides, GAVQNEITL and TINYTIFKI, in separate experi-
target cells infected with rVV expressing HCV proteins ments, according to the protocol of Cerny et al. (1995b).
(Figure 3). Assays using autologous BLCL (expressing Unfortunately, no HCV-naive animals typed for B*1701
all six class I allotypes) identified five CTL lines that and B*2001 were available to serve as controls. After 2
exhibited HCV specificity, with epitopes in three regions weeks of peptide stimulation, cultures of PBMC were
of the HCV polyprotein. In these experiments, the lines tested for peptide-specific cytolytic activity against trans-
of liver-derived CTL were found to operate as clones, fectant targets in the presence and absence of respec-
as seen before (Erickson et al., 1993; Cooper et al., 1996; tive peptides (Figure 4). Cytotoxicity was only observed
Kowalski et al., 1996). To specify their class I restriction, against GAVQNEITL-loaded, Patr-B*1701-expressing tar-
we first sequenced Todd's class I (Patr-A, B, and C) gets. After two further rounds of weekly restimulation
alleles and established six transfected cell lines, each with GAVQNEITL, specific cytotoxicity was enhanced
stably expressing one class I allotype. These cells were and shown to recognize endogenously processed anti-
used as targets following infection with rVV or sensiti- gen with similar efficiency (Figure 4), suggesting that
zation with exogenous peptides (Cooper et al., 1996; the cytolytic activity was unlikely to represent a primary
Kowalski et al., 1996). When rVV-infected target cells T cell response. This indicated that CTL with 4A-like
expressing the appropriate HCV protein were tested specificity were recoverable from Todd's peripheral
against the respective CTL lines, their class I restriction blood z1.5 yr after resolution of infection and provided
was clearly demonstrated (Figure 3). Therefore, during evidence for the existence of HCV-specific T cell mem-
acute hepatitis C in Todd, both the Patr-A0402 and ory. A second attempt to restimulate 3C-like activity
A0601 and the Patr-B1701 and B2001 allotypes re- using TINYTIFKI also failed, implying either that this
stricted the HCV-specific CTL response. CTL lines 6C specificity was absent from Todd's peripheral blood or
present at lower frequency.and 1F were found to possess the same specificity.
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Table 1. HCV Epitopes of CTL Lines from Todd's Week 11 Liver Biopsy
Patr Class I HCV Protein
CTL Line Restriction HCV Epitope Antigen
4A B*1701 1629-GAVQNEITL-1637 NS3
3C B*2001 622-TINYTIFKI-630 E2
2B A*0601 651-RCDLEDRDRSELSPL-665 E2
6C A*0402 306-CSIYPGHITG-315 E1
1F A*0402 nd rVV1
nd, epitope not determined. Numbers adjacent to peptide epitopes indicate coordinates within the HCV-1 polyprotein.
Identification of HCV-specific memory CTL in the pe- tested for HCV specificity using autologous BLCL tar-
gets infected with the rVV vectors (Figure 5). Remark-ripheral circulation encouraged us to seek virus-specific
CTL within liver tissue. Since HCV-specific T cell re- ably, 28 (23%) of Todd's lines were HCV specific and
from LouLou the proportion was even greater: 36 (36%).sponses appear principally focused in the liver (Min-
utello et al., 1993), we considered that memory cells Furthermore, virtually all regions of the polyprotein were
recognized. These CTL likely represent antigen-experi-might be similarly sequestered. However, when liver-
derived CD81T cells were tested in bulk for HCV specific- enced repertoires.
The four CTL specificities defined from Todd's weekity, little or no activity was detectable (data not shown).
But because assays using bulk CTL can fail to demon- 11 biopsy provided a reference for screening memory
T cells for reactivity against the same epitopes. Thesestrate low-frequency specificities, we set out to analyze
the intrahepatic T cell repertoire more rigorously by es- experiments revealed that all four specificities estab-
lished during resolution of acute hepatitis continued totablishing a large panel of liver-derived CD81 T cell lines.
be represented more than one and a half years later
(Figure 5). Using synthetic peptides corresponding toRecovery of HCV-Experienced CD81CTL
Lines from Postinfection Livers recombinant HCV antigens recognized by the remaining
T cell lines, five additional specificities were also identi-CD81 T cells were extracted from liver biopsies taken
from Todd and LouLou, 81 and 55 weeks, respectively, fied. The memory repertoire therefore comprised at least
nine specificities and antigen presentation by all sixfollowing termination of infection. From each individual,
CD81 cells were seeded into 960 wells and stimulated class I molecules (Figure 5). All of these CTL lines were
also found to express CD45RO (data not shown), indicat-with anti-CD3, IL-2, and irradiated PBMC from healthy
HCV seronegative human donors. Cells expanded in 122 ing that they had been generated by TCR-mediated acti-
vation. Collectively, these data indicate that a repertoireof Todd's sample wells and in 102 from LouLou were
Figure 4. Persistence of HCL-Specific CD81
CTL More Than 1 Yr after Acute Hepatitis C
Infection
(A) Cytotoxic activity of Todd's PBMC after
separate restimulations with 2 HCV peptide
epitopes, GAVQNEITL and TINYTIFKI. Using
the protocol of Cerny et al. (1995b), six wells
each containing 4 3 106 fresh PBMC were
restimulated weekly. At the end of the second
week, these cultures were used as a potential
source of specific CTL activity against autolo-
gous BLCL in the presence and absence of
respective epitopic peptides. Duplicate tar-
gets were incubated for 4 hr with effectors at
a fixed E:T of 50:1. A significant response
(.15% specific lysis) was observed in 1 of 6
GAVQNEITL-stimulated wells (well 4) but in
none of the wells restimulated with TINYTI
FKI. Duplicate experiments yielded the same
result (data not shown).
(B) After two further peptide restimulations,
CTL expanded from well 4 were tested
against autologous BLCL that were either ex-
ogenously loaded with peptide or infected
with vaccinia viruses expressing endoge-
nously processed antigen. Targets loaded
with GAVQNEITL or infected with rVV4, ex-
pressing the HCV protein (NS3) containing
that peptide, were killed with similar effi-
ciency, whereas targets infected with wild-
type (wt) VV or not loaded with peptide were
not killed.
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Figure 5. Virus Specificity of CD81T Cell Lines Expanded from Postinfection Liver Tissue Biopsied from Todd and LouLou
Only those lines displaying HCV specificity are shown, and those with identical specificities are grouped together. Respective values of specific
cytotoxicity were determined using 4 hr 51Cr release assays and are indicated in the figure. For each CTL line, values of percent specific lysis
against each of the rVV recognized are separated by a backslash. Cytotoxicity against more than 1 rVV maps the epitope to the region of
overlap.
(A) Specificities, MHC (Patr) class I restriction and HCV-antigenic determinants of CTL lines expanded from a normal liver biopsy taken from
Todd 78 weeks after termination of viremia and normalization of ALT. Of 122 CTL lines tested in cytotoxicity assays, only the 28 displaying
HCV specificity are shown here. The number allocated to each CTL line is indicated. Patr class I restriction and HCV peptide epitopes were
determined for most lines. Specificities that correspond precisely with those detected during acute hepatitis (week 11) are indicated by the
superscripted symbol D. ² indicates CTL lines that lost viability during study. ? denotes CTL lines whose epitopes remain refractory to mapping
using exogenous peptide loading of targets.
(B) Cytotoxic activity of HCV-specific CTL lines expanded from a normal liver biopsy obtained from LouLou ≈1 yr after termination of viremia
and normalization of ALT. 102 CTL lines were tested: 36 displayed HCV specificity and are shown here. The rVV specifically recognized are
indicated according to the assigned nomenclature depicted in the lower panel of Figure 1.
of HCV-specific CD81 T cells persists, mainly (though and LouLou, we examined a possible role for class I
polymorphism in influencing anti-HCV responses.not exclusively) in the liver for an extended period follow-
ing successful resolution of HCV infection. It should be
emphasized that the memory CTL identified in Todd and MHC Class I Typing in a Cohort of Chimpanzees
Inoculated with HCVLouLou were extracted from healthy livers (determined
by biochemical, histological, and ultrastructural criteria Sequence-based typing of MHC class I genes was con-
ducted on the six chimpanzees studied and extended toat multiple timepoints). Because in chronic hepatitis C
HCV continues to generate new CTL specificities, we include an additional 15 that were previously challenged
with HCV. In total, 52 alleles (19 Patr-A, 19 Patr-B, anddid not examine late timepoint CTL repertoires in ani-
mals that failed to control infection. 14 Patr-C) were identified in these 21 individuals, reveal-
ing a level of polymorphism comparable to that foundSince antigen presentation to CTL by MHC class I
molecules appeared to mediate HCV resolution in Todd in human populations (Table 2).
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Table 2. MHC Class I Alleles of Chimpanzees Inoculated with HCV-1
Chimpanzee Patr-A Locus Patr-B Locus Patr-C Locus Virus Dose Outcome Vaccinated
(CID50)
LouLou Ba A*0601 B*0101, B*0402 C*0401, C*1401 10 Resolved Mock
Todda A*0601, A*0402 B*1701, B*2001 C*0601,C*0602 64 Resolved None
Eve A*0601, A*1501 B*1702, B*0101 C*0601, C*0701 10 Resolved Yes
Jena A*0201 B*1701, B*0501 C*0601 10 Resolved Yes
Miss Eve A*1601 B*1703, B*1801 C*0901, C*1001 100 Resolved Yes
Kareem A*0101, A*0802 B*1602, B*1901 C*0501, C*1302 10 Resolved Yes
Dali A*0301, A*0803 B*2301, B*2401 C*0901 10 Resolved Yes
Fred Astaire A*1502, A*1801 B*1202, B*2301 C*0303, C*0901 10 Protected Yes
Briggsiea A*0101, A*0901 B*0101, B*1602 10 Chronic Yes
Cheryl Ba A*0701, A*1401 B*0501, B*2001 C*0602 10 Chronic Yes
Winnya,c A*0701 B*0802 10 Chronic Yes
Hulka A*0401, A*0101 B*0101, B*1701 C*0401, C*0601 10 Chronic Yes
Ross A*0401, A*1401 B*1601, B*1701 C*0501, C*0601 100 Chronic Yes
Blair A*0401, A*1101 B*0101, B*1301 C*0301, C*0401 1 Chronic None
Harry A*0701 B*0501, B*0901 C*0601, C*1101 10 Chronic Yes
Nemo A*0701, A*1401 B*0101, B*0501 C*0401, C*0601 10 Chronic None
Buckwheat A*0701, A*1701 B*0802, B*2201 C*0202, C*0902 10 Chronic None
Mahoneyb A*0102, A*0301 10 Chronic Yes
Mouse A*0301, A*0901 B*0101, B*0502 C*0401, C*0601 10 Chronic None
Reggieb 100 Chronic None
Termiteb 10 Chronic None
Bold type indicates Patr-A or -B alleles found in $3 resolvers.
a Denotes chimpanzees studied prospectively.
b Shown by allele-specific PCR typing to be negative for Patr-B*17 alleles.
c Challenged with HCV-H.
The resolvers, Todd, LouLou, and Eve, share the Patr- for study. For LouLou, the current experiment therefore
represented resolution following rechallenge. This his-A*0601 allele, which was not found in any chronically
infected animal. Also, among the seven chimpanzees tory makes the contrast between her feeble antibody but
potent CTL response particularly striking. If LouLou'sthat resolved hepatitis C, four, including Todd, were
found to share Patr-B*17 allotypes, which were uncom- earlier infection had primed CD81CTL and facilitated
HCV clearance during the recent infection, this wouldmon among chronics (2/13) (Table 2). The Patr-B*17
family of allotypes has a distinctive structure not seen in imply that CTL also played a role in defeating the earlier
infection. Todd had also been previously exposed toother Patr-B or any HLA-B allotypes. The two chronically
infected animals possessing Patr-B*17, Ross and Hulk, HCV, but repeated RT-PCR and liver biochemical assays
at that time provided no evidence for viremia or hepatitis.are half-brothers and share the same Patr-B*1701-con-
taining haplotype, A*0401-B*1701-C*0601. The resolvers, Nonetheless, it remains possible that Todd made an
immune response upon his first viral exposure and thatTodd, Jena, Eve, and Miss Eve, are unrelated, and their
Patr-B*17-containing haplotypes are different from the this vaccinated him. In that case, the CTL response
we observed would represent a protective secondaryone shared by Ross and Hulk.
response. In either case, the similarity in the HCV-spe-
cific immune responses in Todd and LouLou reinforcesDiscussion
the view that CD81CTL, not antibodies, correlate with
immunity in the animals we studied.By studying immune responses during the early phase
of HCV infection, we have obtained evidence suggesting Evidence that human HCV resolution can also occur
independently of antibodies comes from documenteda mechanism of protective immunity. A CTL response
directed by multiple class I allotypes against different cases of hepatitis C in agammaglobulinemic children
(Bjoro et al., 1994; Adams et al., 1997; Christie et al.,regions of the HCV polyprotein correlated with termina-
tion of hepatitis C in both resolvers. Every effort was 1997). These show disease termination in ≈15%, a pro-
portion similar to that anticipated in the general popula-made to verify resolution in Todd and LouLou. Whereas
in human hepatitis C, resolution is determined by suc- tion. The twin study by Adams et al. also supports the
possibility of a genetic influence over disease outcome.cessive tests indicating normal liver function and nega-
tive RT-PCR, in our study chimpanzees these tests were That both Todd and LouLou made such feeble antibody
responses was surprising, and it is notable that LouLousupplemented by light and electron microscopy of liver
biopsies. Over a period of z1.5 yr, Todd and LouLou has no serological marker to indicate either recent infec-
tion with HCV-1 or past infection with HCV-J1. Similarhave shown no evidence of hepatitis or viremia. In con-
trast, persistent viremia and hepatitis remain readily findings were recently observed by Bassett et al. (1998)
among chimpanzees that had resolved infection withdemonstrated in animals designated chronically in-
fected. HCV-H (which exhibits a higher resolution rate than
HCV-1) and inferred in humans who also may have re-In 1992, LouLou had resolved infection with a heterol-
ogous virus (HCV-J1), and this made LouLou attractive solved HCV infection (Kuo et al., 1989; Cerny et al.,
Immunity
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1995a; Koziel et al., 1997). The inverse nature of CTL restricted one specificity and both Patr-C allotypes re-
stricted the same specificity. Some epitopes are rela-and antibody immunity raises the possibility that strong
Th1 responses in HCV resolvers suppress Th2 responses. tively conserved, others display considerable variation.
It seems possible that only when certain class I allotypesIndeed, in view of the strong CD81CTL responses ob-
served in Todd and LouLou, it is likely that CD41 T cell are in combination (for example Patr-A*06 and B*17) are
they advantageous. The possibility that class I polymor-responses, of Th1-type, are important determinants of
HCV resolution, as suggested by studies of HCV clear- phism might influence the outcome of human hepatitis C
is supported by recent studies of patients with persistentance in humans (Diepolder et al., 1995; Missale et al.,
1996). HCV infection (Kuzushita et al., 1998). Taken together,
these data suggest that extensive HLA class I typingOur data suggest that one critical factor for resolution
is the number of CTL specificities that are synchronously studies could correlate differential outcomes of hepatitis
C with particular HCV genotypes and HLA haplotypes.operational in early infection (Figure 1). In Todd, nine
distinct CTL specificities were revealed. Since antibod- This study provides a dissection of a host immune
response that has successfully defeated HCV. Theies did not appear to have contributed to resolution,
these CTL seem to have been adequate to control the quantitative and kinetic aspects of successful CTL re-
sponses shown here propose a model of HCV immunityentire HCV-1 quasispecies. Based on these and other
data (Missale et al., 1996), we envisage a ªthresholdº of that can be examined by further experimentsÐwhich
could facilitate development of vaccines and immuno-CTL response above which the likelihood of viral escape
becomes negligible. The response in Todd and LouLou therapies.
must have exceeded this threshold. By similarly quanti-
Experimental Procedurestating responses in other resolvers, it could be possible
to determine parameters for successful outcome.
AnimalsIn chronic infection, a stuttering pattern of CTL emer-
Chimpanzees were maintained under standard conditions for hu-
gence seems unable to eradicate HCV, in part due to mane care (Moor-Jankowski and Mahoney, 1989) at two facilities:
quasipecies diversity. During evolution to the chronic LEMSIP (Laboratory for Experimental Medicine and Surgery in Pri-
state, at least some CTL select for viruses that have lost mates), New York University Medical Center, Tuxedo, New York,
and Whitesands Research Center, Alamogordo, New Mexico.their target epitopes (Weiner et al., 1995). Fixation of
such substitutions can occur in weeks, but cognate CTL
Immunization and HCV Challengeendure despite epitope loss. Therefore, the number of
The protocols for immunization of animals with recombinant HCVspecificities elicitable at a given time in chronic infection
proteins and challenge with HCV-1/910 virus stock are described
might overestimate the number that are contempora- elsewhere (Choo et al., 1994). Todd had been previously challenged
neously functional. Additionally, it is worth noting that with one chimpanzee-infectious-dose (CID50) of HCV-1 in 1992, but
evidence for infection was never established. In 1995, Todd waswhen examined in bulk, CTL responses tend to wane
again challenged with 64CID50 of HCV-1 that had been preincubatedfollowing HCV resolution but gradually expand in persis-
with hyperimmune sera. In 1993, LouLou had also been previouslytent infection (Figure 1; unpublished data). Our results
inoculatedÐwith 1CID50 of HCV-J1 strain (Okamoto et al., 1992)Ðsuggest that early responses are critical, while observa-
and rapidly resolved acute hepatitis. In 1996, LouLou was only mock
tion at ªlateº timepoints might reveal either no difference immunized and then inoculated with 10CID50 of HCV-1. The infection
between chronics and resolvers or even a broader CTL courses reported here for Todd and LouLou relate to the most recent
viral challenges. CherylB and Winny were each inoculated withresponse in chronically infected individuals.
10CID50. Briggsie was passively immunized with 640 mg of a polyva-It is striking that we recovered extensive repertoires
lent human immunoglobulin preparation that contained anti-E1/E2of HCV-specific CTL from two livers that were biochemi-
antibodies and then inoculated with 10CID50 of HCV-1 24 hr later.cally and histologically normal for more than 1 yr after
Hulk was vaccinated with HCV envelope glycoproteins and then
HCV became undetectable in serum. These characteris- inoculated with 10CID50 of HCV-1. Before challenge, HCV RNA, liver
tics distinguish Todd and LouLou from a recently re- enzymes, and liver histology were repeatedly normal in all animals,
and no HCV-specific CTL or antibodies were detectable, other thanported group of chronic hepatitis C patients having viral
the vaccine-induced anti-E1/E2 antibodies in Hulk (Figure 2).RNA that is detectable only in liver and not in serum
(Dries et al., 1999). This patient subgroup displayed in-
HCV Multi-Antigen ELISAtermittent transaminase elevations and histological hep-
The HCV multi-antigen ELISA was designed to detect individual
atitis. The mechanism by which antigen-specific T cells HCV-specific antibodies including anti-core (C22c), E2, NS3 (C33C),
persist in the healthy livers of Todd and LouLou is uncer- NS4 (C100c), and NS5 regions (as described in Chien et al., 1992;
tain, however, and the possibility of viral antigen persis- Chien, 1993). The sensitivities to each individual antigen are greater
than the individual components of the licensed third generationtence in some form cannot be excluded. Conceivable
ELISAs (Abbott or Ortho), which only include core, NS3, and NS5is that the health of the liver following viral hepatitis
antigens. We have never observed antibodies against HCV envelopemight not require complete elimination of all viral ge-
hypervariable regions (anti-HVR) among samples that are anti-E2
nomes/proteins. negative. Also, we have previously failed to demonstrate correla-
Although the size of our chimpanzee cohort precludes tions between HVR antibodies and HCV immunity; therefore, anti-
HVR reactivities were not specifically sought in this study.statistical inferences regarding genetic determinants of
HCV outcome, it is intriguing that in a group displaying
Recombinant Vaccinia Virusesconsiderable class I polymorphism, 5/7 unrelated re-
Overlapping portions of the HCV-1 genome expressed by recombi-solvers shared alleles that were uncommon or not pres-
nant vaccinia viruses (rVV) used in these experiments are depicted
ent in chronics (Table 2). No single allele seemed protec- in Figure 1. The protocol for establishing such rVV constructs can
tive. It is notable that Todd's Patr-A allotypes each be found in Ralston et al. (1993). The control vector, V4C, did not
contain HCV sequences.restricted three CTL specificities, whereas each Patr-B
A Correlate of Immunity against Hepatitis C Virus
447
Cloning, Sequencing, and Analysis of Patr Class I cDNA CTL Lines. Established by seeding CD81 cells extracted from liver
biopsies into 96-well round-bottom plates at ≈50 cells/well in 200Isolation of total RNA from B cell lines (BLCL), first-strand cDNA
synthesis, Patr class I amplification, cloning into M13, and bi- ml TCM as described (Erickson et al., 1993). From convalescent liver
biopsies, CD81 cells were seeded at two concentrations: 50/welldirectional sequencing of multiple clones per allele was performed
as described (Domena et al., 1993). For efficient amplification and and 200/well, each in 5 3 96 wells. Culture expansion rates were
comparable between each set of plates. In establishing these conva-sequencing of the structurally divergent Patr-B*17 alleles, however,
the following additional primers were respectively required (all lescent CD81 lines, the Pharmacia IL-2 preparation was substituted
by human T-stim (without PHA: Collaborative Biomedical Products).59→39): B17FSP, GCCCGTCGACAGACGCCGAGATGATGGTCATA
GCC; B17ME3S, TGGCAAGGATTACCTTGCCCTG; and B17E2S, Half of the medium in each well was replaced with TCM at 3±4 day
intervals using a clean pipette tip for each well to preclude cellAGGGGCCTGAGTATTGCGAC. In addition, all PCR reactions in-
cluded TaqExtender (Stratagene) in 1:1 stoichiometry with Taq, transfer. Cells that expanded were transferred to 24-well plates
and subjected to a further round of nonspecific restimulation aswhich reduced the frequency of misincorporation errors. All PCR
products were purified using QiaAmp columns. Sequence analysis described, and 100 ml of each cell suspension was tested for cyto-
toxicity against autologous BLCL targets infected with rVV express-was performed using GCG software (Genetics Computer Group),
and a consensus sequence was derived by sequencing $3 clones/ ing overlapping regions of the entire HCV polyprotein.
HCV-Specific CTL from PBMCallele. A cDNA clone identical to the consensus sequence could
then be selected. Expanded by stimulation with known peptide epitopes according
to the protocol of Cerny et al. (1995b).
Cells and Cell Lines
Peptides
Immortalized BLCL
Peptides were synthesized by Chiron mimotopes (Clayton, Australia)
Derived as described in Lawlor et al., (1990).
or Research Genetics using Fmoc solid phase methods. All peptides
Patr Class I Transfectants
had free NH2 and COOH termini.Established by transfecting cDNA into the class I±deficient human
BLCL 721.221 (Shimizu and DeMars, 1989) using the integrating
Cytotoxicity Assaysvector pBJ1neo (Lin et al., 1990). Error-free Patr class I cDNA inserts
Liver-derived CD81 cells were tested for cytolytic activity againstwere excised from 10 mg of the replicative form of M13 by digestion
either autologous BLCL or Patr class I transfectant targets (5 3 103with Sal1 and Hind111 (Boehringer Mannheim), purified from 0.8%
targets/assay) in standard Na251CrO4 (51Cr) release assays. Varyingagarose/TAE gels using Elu-Quick (Schleicher and Schuell), and
ratios of CD81 cells: targets (E:T) were assayed as indicated. Tosubcloned into Xho1/Hind111-digested pBJ1-neo. After amplifica-
determine the presence of HCV specificity among expanding CTLtion in DH5a, recombinants were identified by digesting plasmid
lines, initial assays were performed using 100 ml of culture suspen-DNA with Hind111 and comparing electrophoretic mobility through
sion tested against autologous BLCL targets infected with rVV ex-a 0.8% agarose gel. Patr class I inserts were then sequenced in the
pressing overlapping regions of the entire HCV polyprotein. Targetvector to verify fidelity and selected recombinants prepared at a
cells expressing recombinant HCV proteins were infected with rVVDNA concentration of 1 mg/ml. BLCL 721.221 were washed in RPMI
at a multiplicity of infection (MOI) of 10 and then labeled with 51Cr1640, counted, and resuspended in ªElectroporation Bufferº (20 mM
and prepared for assay as described (Erickson et al., 1993). WhenHepes, 137 mM NaCl, 5 mM KCl, 0.7 mM Na2HPO4, and 6 mM
synthetic peptides were tested for ability to sensitize targets fordextrose) at 40 3 106 cells/ml. Using the BTX electroporation system
lysis, two approaches were taken depending on the number of differ-(BTX), 10±20 mg plasmid DNA was added to 250 ml 721.221 cell
ent targets: for few targets, cells were coincubated with peptidessuspension in a 2 mm gap cuvette, finger mixed, and incubated at
and 51Cr (for 1 hr) and then washed (33) before aliquoting at 5 3room temperature for 10 min. No DNA and vector-only controls were
103/well; for many targets, cells were 51Cr-labeled first, then washedalways included. Cuvette contents were electroporated with a 350
and aliquoted, and then incubated with respective peptides for 1V pulse at 360 mv and 50 mF followed 30 s later by an identical
hr before adding CTL. Six to ten micrograms of each peptide wassecond pulse, then transferred into 3.5 ml RPMI 1640/30%FCS (RM)
usually incubated with each target, although in some cases up toand split equally into two wells of a 24-well plate. Six hours later,
30 mg was required for efficient sensitization. Supernatants were1 ml respective supernatants were removed, and then cultures were
harvested after 3 hr for assays using CTL lines or 4 hr for bulk CTL.resuspended and divided into four wells that were made up to 2
Percent specific 51Cr release was calculated:ml/well with fresh RM. The following morning, each set of four wells
[(Experimental release2Spontaneous release)]/(Maximum re-was again split and fed. One day later, all healthy cultures were
lease2Spontaneous release)] 3 100resuspended in RM containing Geneticin at 1.5 mg/ml active drug
(ªSMºÐwhich was pH adjusted using 5 M NaOH). Typically, cultures
Monitoring of Chimpanzeesrequire additional replacement of SM 31 to 32 before becoming
At the timepoints indicated, published procedures were followed inªquiescent.º After a median of 12 days, G418-resistant cells require
measuring circulating HCV antibodies (Kuo et al., 1989; Chien et al.,feeding. Expanding cells were sorted on the basis of Patr class I
1992), serum alanine aminotransferase (ALT) levels (Muchmore etexpression determined by flow cytometry using the fluorescein-
al., 1988), and HCV RNA (Gretch et al., 1993) in plasma (drawnlabeled mAb W6/32 as described in Kowalski et al., (1996).
in EDTA) and peripheral blood lymphocytes. Liver biopsies wereIntra-Hepatic CD81 T Cells
examined under light and electron microscopy for evidence of in-Obtained from chimpanzee liver biopsies at different timepoints.
flammatory and ultrastructural changes, respectively, as describedCores of liver, obtained using a 16G Menghini needle, were washed
(Muchmore et al., 1988).and then ªgentlyº homogenized in PBS/1%FCS and CD81 cells
affinity extracted using anti-CD8 antibodies bound to magnetic
Acknowledgmentsbeads as described in Erickson et al. (1993).
Bulk CTL. When CD81 cells were destined to be assayed in bulk
S. C. is a Fellow of the American Arthritis Foundation. Research atfor HCV specificity, all recovered cells (typically 0.4±0.5 3 106/
Stanford was supported by National Institutes of Health grant AI-biopsy) were incubated initially in one well of a 24-well plate in 2
17892. Research at Chiron Corporation was funded by Chiron. Theml ªT cell medium (TCM)º comprising RPMI 1640 (GIBCO), 10%
authors thank Markus Uhrberg and Salim Khakoo for critically read-heat-inactivated FCS (Hyclone), 100 U/ml recombinant human IL-2,
ing the manuscript and Jim Mahoney (formerly at LEMSIP) and5% IL-2 purified from supernatants of PHA-stimulated human PBMC
Ali Javadian at Whitesands for invaluable assistance in obtaining(Pharmacia), and antibiotics (penicillin and streptomycin). The well
chimpanzee blood and tissue samples. S. L. C. also thanks Xavieralso received 2 3 106 irradiated human PBMC as feeder cells and
Paliard and Barbara Doe for technical advice and stimulating dis-anti-CD3 mAb (Immunotech) at a final concentration of 0.05 mg/ml.
cussion.Cultures were fed and expanded as indicated every 3±4 days until
reaching a cell number ($6.0 3 106) when they could be assayed
against the target panel. Received January 20, 1999; revised March 8, 1999.
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